Generic Nocdurna Availability
Last updated on Sep 11, 2024.
Nocdurna is a brand name of desmopressin, approved by the FDA in the following formulation(s):
NOCDURNA (desmopressin acetate - tablet;sublingual)
-
Manufacturer: FERRING PHARMS INC
Approval date: June 21, 2018
Strength(s): 0.0277MG (discontinued) [RLD], 0.0553MG (discontinued) [RLD]
All of the above formulations have been discontinued.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nocdurna. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods comprising desmopressin
Patent 10,137,167
Issued: November 27, 2018
Inventor(s): Klein Bjarke Mirner & Norgaard Jens Peter
Assignee(s): Ferring B.V.The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period.
Patent expiration dates:
- May 21, 2029✓
- May 21, 2029
-
Methods comprising desmopressin
Patent 11,020,448
Issued: June 1, 2021
Inventor(s): Klein Bjarke Mirner & Norgaard Jens Peter
Assignee(s): FERRING B.V.The present disclosure is directed to reducing nocturnal voids by administering a dose of desmopressin over a minimum treatment period compared to before administration, and maintaining or improving the reduction of nocturnal voids over the minimum treatment period.
Patent expiration dates:
- May 21, 2029✓
- May 21, 2029
-
Patent 11,963,995
Patent expiration dates:
- May 21, 2029✓
- May 21, 2029
-
Patent 7,560,429
Patent expiration dates:
- February 2, 2024✓✓
- February 2, 2024
-
Methods comprising desmopressin
Patent 9,974,826
Issued: May 22, 2018
Inventor(s): Klein Bjarke Mimer & Norgaard Jens Peter & Shumel Brad
Assignee(s): Ferring B.V.The present disclosure is directed to gender, age, and dose effects of desmopressin on reducing nocturnal voids, increasing an initial period of undisturbed sleep, and/or reducing nocturnal urine volume.
Patent expiration dates:
- April 13, 2030✓
- April 13, 2030✓
- April 13, 2030
More about Nocdurna (desmopressin)
- Nocdurna consumer information
- Check interactions
- Compare alternatives
- Pricing & coupons
- Imprints, shape & color data
- Latest FDA alerts (2)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: antidiuretic hormones
- Breastfeeding
- En español
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.